Compare Dynatrace Inc. Common Stock (DT) vs Dyne Therapeutics Inc. Common Stock (DYN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dynatrace Inc. Common Stock vs Dyne Therapeutics Inc. Common Stock — how do they compare? Dynatrace Inc. Common Stock trades at $63.33 (market cap $18.63B), while Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B). The key difference: Dynatrace Inc. Common Stock is far larger — about 6.5× Dyne Therapeutics Inc. Common Stock's market cap, and Dynatrace Inc. Common Stock is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dynatrace Inc. Common Stock for 3 Days and Dyne Therapeutics Inc. Common Stock for 0 Days on average.
| DT | DYN | |
|---|---|---|
Market Cap | $18.63B | $2.86B |
Volume | 8,438,411 | 3,341,579 |
Sector | Technology | Health |
52-Week High | $65.25 | $26.78 |
52-Week Low | $32.36 | $14.60 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $17.68B | $2.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dynatrace (DT) trades at $64.46, down 1.21% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported robust revenue growth to $1.70B in 2025 and has consistently beaten earnings estimates, though its valuation ratios like a P/E of 128.94 are elevated. Recent developments include achieving FedRAMP certification and completing the acquisition of Arize, enhancing its AI observability platform.
The outlook is positive given strong analyst support (85.71% buy ratings) and a consensus price target of $62.44, though risks include high valuation sensitivity and projected net income decline in 2026. Earnings growth and federal market expansion are key catalysts, but investors should monitor execution against lofty expectations.
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dynatrace Inc. Common Stock
Dynatrace provides an observability, security, and automation platform for cloud and IT environments. Its platform integrates data such as logs, metrics, and traces to help organizations monitor digital systems.
Read more on DT →About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →
